Healthcare

US permits emergency use of coronavirus antibody drug

By Mike Brest
Published November 10, 2020 2:24pm ET
Add Washington Examiner on Google
US permits emergency use of coronavirus antibody drug
President Trump signed into law the FDA Reauthorization Act of 2017 on Friday. It reauthorizes a program in which drug and device makers pay the FDA a fee for every new product application, and the agency uses that money to hire more people and speed up approvals. (AP Photo/Andrew Harnik, File) | Andrew Harnik

The Food and Drug Administration has authorized the emergency use of a coronavirus antibody treatment for certain patients.

On Monday, the FDA approved Eli Lilly & Co’s bamlanivimab drug based on trial data that showed a lowered rate of hospitalizations after a one-time use of the treatment. The treatment has not been authorized for universal use among COVID-19 patients, but it will be given to adults 65 years or old or people over the age of 12 with existing health conditions.

Already a print subscriber? Click here to login/register your account

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.

Tag:

COVID-19 FDA Vaccines